Trial Profile
Safety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Canada
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Sep 2017
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
- Focus Therapeutic Use
- Acronyms BIOFLOW-III
- Sponsors BIOTRONIK
- 19 Sep 2017 Status changed from recruiting to completed.
- 12 May 2015 New trial record